Lipid emulsion rich in n-3 polyunsaturated fatty acids elicits a pro-resolution lipid mediator profile in mouse tissues and in human immune cells
| Autor: | Noureddine, Nazek, Hartling, Ivan, Wawrzyniak, Paulina, Srikanthan, Pakeerathan, Lou, Phing-How, Lucchinetti, Eliana, Krämer, Stefanie D, Rogler, Gerhard, Zaugg, Michael, Hersberger, Martin |
|---|---|
| Přispěvatelé: | University of Zurich |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Nutrition and Dietetics
Docosahexaenoic Acids Medicine (miscellaneous) 610 Medicine & health 2701 Medicine (miscellaneous) Dehydroepiandrosterone n–3 PUFA n–6 PUFA inflammation total parenteral nutrition specialized pro-resolving mediator (SPM) prostaglandins leukotrienes endocannabinoids Mice 10219 Clinic for Gastroenterology and Hepatology 10036 Medical Clinic 10076 Center for Integrative Human Physiology Fatty Acids Omega-3 Fatty Acids Unsaturated Animals Humans 2916 Nutrition and Dietetics Emulsions Endocannabinoids |
| Zdroj: | The American Journal of Clinical Nutrition, 116 (3) |
| ISSN: | 0002-9165 |
| Popis: | Background Lipid emulsions are a key component of total parenteral nutrition (TPN) and are administered to patients who are unable to ingest their daily required calories orally. Lipid emulsions rich with n–6 (ω-6) PUFAs are known to cause parenteral nutrition–associated liver disease and have inflammatory side effects, whereas n–3 PUFA-rich emulsions have favourable clinical outcomes. Objectives The present study used targeted lipid mediator analysis to investigate the metabolism of a n–3 PUFA-rich lipid emulsion and a n–6 PUFA-rich lipid emulsion in a mouse model of TPN and in primary human monocyte-derived macrophages (MDMs) and CD4+ T cells. Results Mice given n–3 PUFA-based TPN for 7 d had a less proinflammatory lipid mediator profile compared with those receiving n–6 PUFA-based TPN. This was characterized by higher concentrations of specialized pro-resolving mediators (SPMs) and endocannabinoids, including resolvin D (RvD) 1, maresin (MaR) 1, MaR2, protectin D1 (PD1), protectin DX (PDX), and the endocannabinoids eicosapentaenoyl ethanolamide (EPEA) and docosahexaenoyl ethanolamide (DHEA) in the liver and RvD1, 17R-RvD1, RvD2, RvD3, RvD5, MaR1, MaR2, PD1, PDX, and EPEA and DHEA in the spleen. The spleen was identified as a source of high lipid mediator and SPM formation as lipid mediator concentrations were on average 25-fold higher than in the liver. Additionally, n–3 PUFA-treated primary human MDMs produced RvD5 and the endocannabinoids EPEA and DHEA, which was associated with an increased IL-10 secretion. In contrast, primary human CD4+ T cells showed only an increase in SPM precursors and an increase in the endocannabinoids EPEA and DHEA, which was associated with reduced cytokine expression. Conclusions This demonstrates that lipid mediators, particularly SPMs and endocannabinoids from spleen, could play a key role in facilitating the favorable clinical outcomes associated with the use of n–3 PUFA-rich lipid emulsions in TPN. ISSN:0002-9165 ISSN:1938-3207 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|